Triple-negative breast cancer (TNBC), endometrial cancer (EC), and epithelial ovarian cancer A precision-targeted medication called pralizumab-ravtansine (CX-2009) is intended to attach to the transmembrane glycoprotein CD166, which is present in both normal and malignant tissues. This evidence concerns the gene GPNMB and triple-negative breast carcinoma.